Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute-graft-versus-host Disease: early-phase trial registry
3 of 8 indexed Acute-graft-versus-host Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Acute-graft-versus-host Disease: 8 US clinical trials tracked, 3 recruiting.
Acute-graft-versus-host Disease is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Regimmune Corporation, running 1 of these trials.
Enrollment posture brief
Registry condition acute-graft-versus-host-disease
OPEN 3 | RECR 38% | LATE 1 | EARLY 5 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Lymphoid Leukemia (38% recruiting · 8 trials)
Acute-graft-versus-host Disease lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute-graft-versus-host Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute-graft-versus-host Disease is recruiting below its size-band peers.
3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute-graft-versus-host Disease trials is spread across many organizations.
Regimmune Corporation accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Acute-graft-versus-host Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 98 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Acute-graft-versus-host Disease research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
MAGIC Ruxolitinib for aGVHD
John Levine
NCT06936566
Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
Dana-Farber Cancer Institute
NCT05236062
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
City of Hope Medical Center
NCT05443425
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
CSL Behring
NCT03805789
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Children's Oncology Group
NCT03057054
Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation
Fred Hutchinson Cancer Center
NCT06026371
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Washington University School of Medicine
NCT02611180
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
Regimmune Corporation
NCT04014790
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute-graft-versus-host Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute-graft-versus-host Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute-graft-versus-host Disease page
8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Acute-graft-versus-host Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Regimmune Corporation sponsors the most Acute-graft-versus-host Disease trials on record, review their full trial history before evaluating a specific study. See Regimmune Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute-graft-versus-host Disease condition card totals 8 registered trials; most-linked intervention RGI-2001; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.